Similar articles

• New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

  Loiseau C, Ali A, Itzykson R. Loiseau C, et al. Exp Hematol. 2015 Aug;43(8):661-72. doi: 10.1016/j.exphem.2015.05.014. Epub 2015 Jun 27. Exp Hematol. 2015. PMID: 26123365 Review.
• [Treatment of MDS].

  Usuki K. Usuki K. Rinsho Ketsueki. 2014 Oct;55(10):1882-92. Rinsho Ketsueki. 2014. PMID: 25297752 Review. Japanese. No abstract available.
• Myelodysplastic syndromes (MDS).

  Klimek V. Klimek V. Best Pract Res Clin Haematol. 2015 Mar;28(1):1-2. doi: 10.1016/j.beha.2014.11.007. Epub 2014 Nov 29. Best Pract Res Clin Haematol. 2015. PMID: 25659724 No abstract available.
• Update on the pharmacotherapy for myelodysplastic syndromes.

  Duong VH, Komrokji RS, List AF. Duong VH, et al. Expert Opin Pharmacother. 2014 Sep;15(13):1811-25. doi: 10.1517/14656566.2014.937705. Epub 2014 Jul 31. Expert Opin Pharmacother. 2014. PMID: 25080144 Review.
• [Molecular target therapy for myelodysplastic syndrome].

  Morita Y, Tanaka H, Matsumura I. Morita Y, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:508-12. Nihon Rinsho. 2012. PMID: 23513892 Japanese. No abstract available.